TWST Jul 2024 35.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
At close: 11:12AM EDT
Loading interactive chart...
- Simply Wall St.
Here's Why We're Not At All Concerned With Twist Bioscience's (NASDAQ:TWST) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. Indeed, Twist Bioscience ( NASDAQ:TWST...
- Zacks
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?
Here is how DaVita HealthCare (DVA) and Twist Bioscience (TWST) have performed compared to their sector so far this year.
- Business Wire
Twist Bioscience Publishes Preclinical Data Detailing Discovery of Antibody Targeting Emerging Checkpoint Inhibitor
SOUTH SAN FRANCISCO, Calif., June 06, 2024--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the publication of a study detailing the discovery of TB206-001, a first-in-class antibody targeting adenosine A2A receptor (A2AR), a promising molecular target that could enhance cancer immunotherapy. The study titled, "Discovery of a potent, selective, and tumor-suppressing
© 2024 Yahoo. All rights reserved.